GH1 and cystic fibrosis: In the first trial, children with CF and malabsorption secondary to exocrine pancreatic insufficiency received four weeks of oral glutamine (0.7 g/kg/day), subcutaneous human recombinant growth hormone (rhGH, 0.3 mg/kg/week), or a combination of both agents.